183 related articles for article (PubMed ID: 36271186)
1. [Short version of the S2k guideline on drug therapy of neurogenic lower urinary tract dysfunction (NLUTD)].
Kutzenberger J; Angermund A; Domurath B; Möhr S; Pretzer J; Soljanik I; Kirschner-Hermanns R
Urologie; 2023 Jan; 62(1):41-52. PubMed ID: 36271186
[TBL] [Abstract][Full Text] [Related]
2. Long-term beneficial effects of mirabegron in pediatric patients with therapy-refractory neurogenic lower urinary tract dysfunction.
van Veen FEE; Schotman M; 't Hoen LA; Blok BFM; Scheepe JR
J Pediatr Urol; 2023 Dec; 19(6):753.e1-753.e8. PubMed ID: 37658014
[TBL] [Abstract][Full Text] [Related]
3. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
McKeage K
Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
[TBL] [Abstract][Full Text] [Related]
4. [Neuro-urological diagnosis and therapy of lower urinary tract dysfunction in patients with spinal cord injury : S2k Guideline of the German-Speaking Medical Society of Paraplegia (DMGP), AWMF register no. 179/001].
Böthig R; Domurath B; Kaufmann A; Bremer J; Vance W; Kurze I
Urologe A; 2017 Jun; 56(6):785-792. PubMed ID: 28314966
[TBL] [Abstract][Full Text] [Related]
5. Detrusor relaxing agents for neurogenic detrusor overactivity: a systematic review, meta-analysis and network meta-analysis.
Zhou Z; Wang X; Li X; Liao L
BJU Int; 2024 Jan; 133(1):25-33. PubMed ID: 37500569
[TBL] [Abstract][Full Text] [Related]
6. Management of neurogenic detrusor overactivity.
Clark CB; Ragam R; Das AK; Shenot PJ
Can J Urol; 2021 Aug; 28(S2):33-37. PubMed ID: 34453427
[TBL] [Abstract][Full Text] [Related]
7. Neurogenic Lower Urinary Tract Dysfunction in Asymptomatic Patients with Multiple Sclerosis.
Jaekel AK; Winterhagen FI; Zeller FL; Butscher AL; Knappe FK; Schmitz F; Hauk C; Stein J; Kirschner-Hermanns RKM; Knüpfer SC
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552016
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury.
Wöllner J; Pannek J
Spinal Cord; 2016 Jan; 54(1):78-82. PubMed ID: 26503222
[TBL] [Abstract][Full Text] [Related]
11. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
Soljanik I
Drugs; 2013 Jul; 73(10):1055-66. PubMed ID: 23775527
[TBL] [Abstract][Full Text] [Related]
13. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study.
Konstantinidis C; Samarinas M; Tzitzika M; Kratiras Z; Panagiotakopoulos G; Giannitsas K; Athanasopoulos A
Neurourol Urodyn; 2021 Nov; 40(8):2026-2033. PubMed ID: 34498773
[TBL] [Abstract][Full Text] [Related]
15. Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.
Ganguly A; Tyagi S; Chermansky C; Kanai A; Beckel J; Hashimoto M; Cho KJ; Chancellor M; Kaufman J; Yoshimura N; Tyagi P
Drugs Aging; 2023 Mar; 40(3):241-261. PubMed ID: 36879156
[TBL] [Abstract][Full Text] [Related]
16. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
17. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
Ineichen BV; Schneider MP; Hlavica M; Hagenbuch N; Linnebank M; Kessler TM
Mult Scler; 2018 Apr; 24(4):529-534. PubMed ID: 28367674
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis.
Xu R; Yang TX; Fang KW; Wang G; Li P
Sci Rep; 2022 Oct; 12(1):17905. PubMed ID: 36289427
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron.
Zachariou A; Filiponi M; Baltogiannis D; Giannakis J; Dimitriadis F; Tsounapi P; Takenaka A; Sofikitis N
Can J Urol; 2017 Dec; 24(6):9107-9113. PubMed ID: 29260636
[TBL] [Abstract][Full Text] [Related]
20. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
